PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life
Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations to the diagnosis and treatment of patients with bronchiectasis, with a goal of identifying and treating underlying causes; Describe the underlying mechanisms believed to contribute to inflammation in non–cystic fibrosis bronchiectasis and their correlation to emerging treatments; Assess recent clinical trial data concerning efficacy and safety of novel and emerging treatment options for non–cystic fibrosis bronchiectasis; and Develop strategies for preventing and treating exacerbations (eg, airway clearance, use of antibiotics, corticosteroids) in patients with non–cystic fibrosis bronchiectasis based on the latest expert recommendations using a personalized approach.